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The cure fraction models are usually used to model lifetime time data with long-term
survivors. In the present article, we introduce a Bayesian analysis of the four-parameter
generalized modiﬁed Weibull (GMW) distribution in presence of cure fraction, censored
data and covariates. In order to include the proportion of “cured” patients, mixture and
non-mixture formulation models are considered. To demonstrate the ability of using this
model in the analysis of real data, we consider an application to data from patients with gas-
tric  adenocarcinoma. Inferences are obtained by using MCMC (Markov Chain Monte Carlo)
methods.ayesian analysis
eneralized modiﬁed Weibull
istribution
ure fraction model
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In addition, other common situation in the analysis of time-.  Introduction
n the lifetime data analysis, researchers commonly use
tandard non-parametrical techniques, such as Kaplan–Meier
stimators or log-rank test [1], semi-parametrical models (for
xample, proportional hazards model in presence of covari-
tes [2] or standard parametrical models using some popular
ifetime distributions [3]. One of the distributions widely used
n cancer research is the Weibull distribution [4], mainly due to
he ﬂexibility of its hazard function and the facility to estimate
∗ Corresponding author. Tel.: +55 1636022569.
E-mail addresses: edson@fmrp.usp.br, edson.martinez@ig.com.br (E
169-2607/$ – see front matter © 2013 Elsevier Ireland Ltd. All rights res
ttp://dx.doi.org/10.1016/j.cmpb.2013.07.021its parameters. However, in medical lifetime research, we
usually have data sets which require more  sophisticated para-
metric models. To achieve this goal, new classes of parametric
distributions based on extensions of the Weibull distribution
have been introduced in the literature. As special cases, we
have the exponentiated Weibull (EW) [5,6], the generalized
modiﬁed Weibull [7] and the log-beta Weibull distributions [8]..Z. Martinez).
to-event data, particularly in cancer research, occurs when
it is expected that a fraction of individuals will not experi-
ence the event of interest. In this case, it is assumed that the
erved.
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studied population is a mixture of susceptible individuals who
experience the event of interest and non-susceptible individ-
uals that supposedly will never experience it. The presence
of immune or cured individuals in a data set is usually sug-
gested by a Kaplan–Meier plot of the survival function, which
shows a long and stable plateau with heavy censoring at the
extreme right of the plot [9]. Different parametric and non-
parametric approaches have been considered to model the
proportion of immunes and interested readers can refer, for
example, to Boag [10], Berkson [11], Haybittle [12], Meeker [13],
Gamel et al. [14], Ghitany and Maller [15], Copas and Heydary
[16], Ng and McLachlan [17], De Angelis et al. [18], Peng and
Dear [19], Lambert et al. [20] and Yu et al. [21]. In addition,
Bayesian inference methods for survival data with a surviv-
ing fraction were introduced by some authors such as Castro
et al. [22], Chen et al. [23], Ibrahim et al. [24], Kim et al. [25]
and Seltman et al. [26]. As a motivation for this paper, we
consider a gastric cancer lifetime data introduced by Jácome
et al. [27]. For a statistical analysis of this data set, we assume
the four-parameter generalized modiﬁed Weibull distribution
(GMW)  [7] in presence of cure fraction, censored data and
covariates. We  implemented the statistical model under a
Bayesian framework, where the parameter estimation is based
on Markov Chain Monte Carlo (MCMC) techniques. We  orga-
nize the rest of the paper as follows. The gastric cancer data set
is described in Section 2. In Section 3, we  describe the mixture
and non-mixture cure fraction models, the GMW distribution
[7] and some of their special cases. In this section we  also
introduce the formulation of the likelihood functions consid-
ering mixture and non-mixture cure fraction models based on
the GMW  distribution. The Bayesian analysis for the proposed
models is described in Section 4. The obtained results of the
Bayesian analysis for this medical data set, considering the
proposed mixture and non-mixture models, are presented in
Section 5. Finally, in Section 6, we  present a discussion of the
obtained results.
2.  The  gastric  cancer  data
Gastric cancer is one of the leading causes of cancer-related
death [28] and the mucosal resection is accepted as a treat-
ment option for early cases of the disease. In a review of the
literature [29], it was found that the 5-year survival rate fol-
lowing all type of resections has increased signiﬁcantly from
20.7% before 1970 to 28.4% before 1990. In addition, the 5-
year survival rate following curative or radical resection has
risen from 37.6 to 55.4% over the same period. Thus, new
technologies to optimize medical decisions and the develop-
ment of new therapies are of great importance to improve
survival in gastric cancer. Jácome et al. [27] conducted a retro-
spective study in patients with gastric adenocarcinoma who
underwent curative resection with D2 lymphadenectomy in
the Barretos Cancer Hospital (Hospital de Câncer de Barretos,
Brazil) between January 2002 and December 2007. The effec-
tiveness of lymphadenectomy for cure in patients with early
gastric cancer and lymph node metastasis is discussed by
Okamura et al. [30]. It is known that adjuvant chemoradiother-
apy (CRT) is the standard treatment in Western countries for b i o m e d i c i n e 1 1 2 ( 2 0 1 3 ) 343–355
gastric cancer patients submitted to curative resection. Aim-
ing a more  precise evaluation of the treatment, Jácome et al.
[27] considered 185 patients with stage II to IV gastric ade-
nocarcinoma with no distant metastases and compared the
3-year overall survival of the two treatments, that is, adju-
vant CRT versus resection alone. In the present article, as an
illustration for the use of the GMW  distribution, we  consider
the entire data set obtained from this study, considering 201
patients of different clinical stages. Table 1 shows this data
set, which includes 76 patients that received adjuvant CRT
and 125 that received resection alone. The data in this table
refer to the times until death in months since surgery, where
a plus symbol (+) indicates censored data. We observe that we
have 53.2% of censored data, that is, 57.9% if we  consider the
patients treated with CRT and 50.4% if we consider the patients
treated with resection alone.
The Kaplan–Meier estimate of the survival function for the
gastric cancer data is given in Fig. 1, where the presence of a
plateau near to 0.5 observed in the graph presented in panel
(a) suggests that models that ignore the proportion p of long-
term survivors will not be suitable for these data. The graph
presented in panel (b) of Fig. 1 describes the empiric survival
functions for each type of treatment, where the presence of
stable plateaus at the right tail of the plot also assures the
adequacy of the cure fraction model approach.
3.  Models
3.1.  Mixture  and  non-mixture  cure  fraction  models
Following Maller and Zhou [31], a mixture model for lifetime
data sets assumes that the probability of the time-to-event
to be greater than a speciﬁed time t is given by the survival
function
S(t) = p + (1 − p)S0(t), (1)
where p is a parameter which represents the proportion of
“long-term survivors” or “cured patients”, regarding the event
of interest (0 < p < 1), and S0(t) is the baseline survival function
for the susceptible individuals [10]. Common choices for S0(t)
are the Gompertz, exponential and Weibull distributions. The
probability density function for the lifetime T is
f (t) = dF(t)
dt
= (1 − p) f0(t),
where F(t) = 1 − S(t) and f0(t) is the baseline probability density
function for the susceptible individuals. Considering a random
sample (ti, ıi) of size n, i = 1, . . ., n, the contribution of the ith
subject for the likelihood function is given by
Li = [f (ti)]ıi [S(ti)]1−ıi = [(1 − p)f0(ti)]ıi [p + (1 − p)S0(ti)]1−ıi ,where ıi is a censoring indicator variable, that is, ıi = 1 for
an observed lifetime and ıi = 0 for a censored lifetime. Alter-
natively, a non-mixture formulation has been suggested by
several authors [32,33]. This model deﬁnes an asymptote for
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Table 1 – Data from 76 patients received adjuvant CRT and 125 receiving resection alone. A plus symbol (+) indicates
censored data.
Treatment Months since surgery
CRT 5.76, 7.89, 8.85, 8.95, 9.05, 9.47, 10.72, 11.97, 12.5, 12.83, 13.09, 13.49, 13.78, 13.82, 14.7, 14.77,
16.38, 16.51, 17.07, 17.14, 17.34+, 17.7, 18.39, 19.21, 19.38+, 20.49+, 20.76+, 21.02, 22.86, 23.39+,
23.82+, 24.21, 24.21+, 24.31, 24.28+, 24.97+, 25.23, 25.33+, 25.56+, 25.59+, 25.76+, 25.79, 25.79+,
26.05, 27.89+, 28.22+, 28.59, 28.65+, 29.08+, 29.31+, 30.26, 30.69+, 30.95+, 31.64+, 31.84+, 32.4+,
32.47+, 32.53+, 33.88+,34.74+, 34.9+, 35.72+, 35.89+, 36.0+,36.0+, 36.0+, 36.0+, 36.0+, 36.0+,
36.0+, 36.0+, 36.0+, 36.0+, 36.0+, 36.0+, 36.0+
Surgery alone 0.1, 0.2, 0.23, 0.26, 0.3, 0.33, 0.49, 0.53, 0.56, 0.63, 0.66, 0.66, 1.18, 1.45+, 1.61, 1.78, 2.63+, 2.73,
2.8, 2.89, 2.96, 3.32, 3.49+, 4.01, 4.54, 4.67, 4.67, 4.93, 6.15, 6.55+, 6.91, 7.17, 7.7, 7.93+, 8.32, 8.36,
8.39, 8.78, 8.91, 9.28, 9.7, 10.03, 10.2, 10.53, 10.76, 11.41, 11.88, 12.5, 13.13+, 13.95, 14.01, 14.05,
14.34, 14.38+, 15.43, 15.76+, 16.09, 16.18, 16.94, 16.94+, 17.14, 17.24, 17.43, 18.62, 19.14, 19.44,
19.84+, 19.93, 20.49+, 21.38+, 21.48, 21.84+, 21.88+, 22.14, 22.99+, 23.39+, 23.52+, 23.55+, 23.85+,
24.01+, 24.57+, 24.8+, 25.26+, 25.3, 25.33+, 25.36+, 26.15+, 26.32, 26.32+, 26.78+, 27.37+, 28.98+,
29.28+, 29.31+, 29.97+, 30.16+, 30.49+, 30.63+, 31.38+, 31.68+, 32.5+, 32.8+, 33.09+, 33.36+, 33.65+,
+, 34.
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he cumulative hazard and hence for the cure fraction. In this
ase, the survival function is given by
(t) = pF0(t) = exp[ln(p)F0(t)], (2)
here F0(t) = 1 − S0(t). Assuming this model, the contribution
f the ith subject for the likelihood function is given by
i = [h(ti)]ıi S(ti) = [−(ln p)f0(ti)]ıi exp[ln(p)F0(ti)],
here h(t) = f(t)/S(t) is the hazard function. In the literature, an
xtensive list of articles on modeling survival data including
ong-term survivors can be found, and interested readers can
efer to Farewell [34], Tsodikov [35], Sposto [36], Cancho et al.
37], Mazucheli et al. [38], Rodrigues et al. [39], Perdoná and
ouzada-Neto [40], among several others.
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3.2.  The  generalized  modiﬁed  Weibull  distribution
Let us assume a generalized modiﬁed Weibull (GMW)  distri-
bution for the susceptible individuals with probability density
function given by
f0(t) = ˛ˇt
−1( + t)  exp[t − ˛t exp(t)]
{1 − exp[−˛t exp(t)]}1−ˇ
, (3)
t > 0, where  ˛ > 0,  ˇ > 0,  > 0 and  > 0. This four-parameter dis-
tribution was introduced by Carrasco et al. [7], and it is ﬂexible
to accommodate many  forms of the hazard rate function,
including bathtub-shaped failure rates data. The respective
survival function is given by
S0(t) = 1 − {1 − exp[−˛t exp(t)]}ˇ, (4)
0 5 10 15 20 25 30 35
0.0
0.2
0.4
0.6
0.8
1.0
(b)
Time (months)
Chemoradiotherapy
Surgery alone
 for the gastric cancer data. (b) Survival functions for each
 s i n346  c o m p u t e r m e t h o d s a n d p r o g r a m
The GMW  distribution is denoted by X ∼ GMW(˛, ˇ, , ). The ˛
parameter is a scale parameter and  ˇ and  are shape param-
eters. Following Carrasco et al. [7], the  parameter is related
to an accelerating factor in the imperfection time and it works
as a factor of fragility in the survival of the individual when
the time increases. The corresponding hazard function for the
lifetimes is given by
h0(t) = ˛ˇt
−1( + t) exp[t − ˛t exp(t)]{1 − exp[−˛t exp(t)]}ˇ−1
1 − {1 − exp[−˛t exp(t)]}ˇ
.
Several standard existing distributions are special cases of
the four-parameter GMW  distribution [7], given as follows:
(a) Weibull distribution: when  = 0 and  ˇ = 1, the expression
(3) is the probability density function of a two-parameter
Weibull distribution.
(b) Exponential distribution: when  = 0,  ˇ = 1 and  = 1, the
expression (3) is reduced to the probability density func-
tion of an exponential distribution. This distribution is
characterized by a constant hazard function given by
h0(t) = ˛.
(c) Rayleigh distribution: when  = 0,  ˇ = 1 and  = 2, the
expression (3) is reduced to the probability density func-
tion of a Rayleigh distribution.
(d) Extreme value distribution: this type I extreme value
distribution [41] is a special case of the GMW distri-
bution with  ˇ = 1 and  = 0. However, when considering
survival outcomes some caution is required because its
support spreads over the whole real line [42]. From (4),
we note that its respective survival function is given by
S0(t) = exp(− ˛et). Thus, we have S0(t) = e−˛ when t = 0, that
is, S0(t = 0) is not equal to 1, as it is expected by considering
survival data. Despite these problems, we also consider
this distribution in the present study.
(e) Exponentiated Weibull distribution (EW): the EW distri-
bution [5,6] is a special case of the GMW  distribution with
 = 0. The statistical properties of the EW distribution are
presented by Nassar and Eissa [43].
(f) Exponentiated exponential distribution (EE): the EE distri-
bution [44] is a special case of the GMW  distribution with
 = 0 and  = 1. Some properties of the EE distribution are
discussed by Gupta and Kundu [45].
(g) Generalized Rayleigh distribution (GR): the GR distribution
[46] is a special case of the GMW  distribution with  = 0 and
 = 2.
(h) Modiﬁed Weibull distribution (MW): Lai et al. [42]
introduced the three-parameter MW distribution, which
is a special case of the GMW  distribution with  ˇ = 1.
Maximum-likelihood estimation of the parameters and
statistical properties of the MW distribution are presented
by Sarhan and Zaindin [47].Carrasco et al. [7] introduced general formulas for the
moments of the GMW  distribution and also commented on
obtaining maximum likelihood estimators for the parameters
of the model and hypothesis tests of interest. b i o m e d i c i n e 1 1 2 ( 2 0 1 3 ) 343–355
3.3.  The  log-likelihood  functions
Assuming the mixture model (1), the log-likelihood function
for  = (p, ˛, ˇ, , ) is given by
l() =
n∑
i=1
[ln(1 − p)]ıi + (ln ˛)
n∑
i=1
ıi +
n∑
i=1
(ln ˇ)ıi + (−1)
n∑
i=1
ıi ln ti
+
n∑
i=1
ıi ln( + ti) + 
n∑
i=1
ıiti − ˛
n∑
i=1
ıit

i
exp(ti)
−
n∑
i=1
(1 − ˇ)ıi ln{1 − exp[−˛ti exp(ti)]}
+
n∑
i=1
(1 − ıi) ln[p + (1 − p)(1 − {1 − exp[−˛ti exp(ti)]}
ˇ)].
(5)
Moreover, assuming the non-mixture model (2), the log-
likelihood function for  is given by
l() =
n∑
i=1
ln(− ln p)ıi + (ln ˛)
n∑
i=1
ıi +
n∑
i=1
(ln ˇ)ıi + ( −1)
n∑
i=1
ıi ln ti
+
n∑
i=1
ıi ln( + ti) + 
n∑
i=1
ıiti − ˛
n∑
i=1
ıit

i
exp(ti)
−
n∑
i=1
(1 − ˇ)ıi ln{1 − exp[−˛ti exp(ti)]}
+
n∑
i=1
{ln(p){1 − exp[−˛t
i
exp(ti)]}ˇ}. (6)
In addition for these models, we also assume that the
parameter p could be related to a vector of covariates xi by
replacing p in the expressions (5) and (6) by
pi =
exp
(
xT
i

)
1 + exp
(
xT
i

) ,
where  is a vector of unknown parameters.
4.  Bayesian  inference
The joint posterior distribution for the parameters of the
model is obtained via Bayes theorem [48] by combining the
joint prior distribution with the likelihood function for .
Although the joint posterior distribution for the parameters
of the proposed model is of great complexity, samples of the
joint posterior distribution can be generated using some exist-
ing MCMC (Markov Chain Monte Carlo) simulation methods.
A great computational simpliﬁcation to simulate these sam-
ples is obtained using the OpenBUGS software, where we
only need to specify the distribution for the data and the
prior distributions for the parameters. For a Bayesian anal-
ysis of the mixture and non-mixture models not including
covariates, we assume a beta prior distribution for the pro-
portion p of the long-term survivors denoted by p ∼ Beta(a,
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) where a and b are known hyperparameters. Observe that
ince the parameter p is deﬁned for values in the interval
0, 1), a natural choice for a prior distribution is given by
 beta distribution. We also assume gamma prior distribu-
ions for the parameters ˛, ˇ,  and  considering that these
arameters are real and positive numbers. Thus, we have
 ∼ Gamma(c˛, d˛),  ˇ ∼ Gamma(cˇ, dˇ),  ∼ Gamma(c , d ) and
 ∼ Gamma(c, d), where c˛, d˛, cˇ,dˇ, c ,d ,c and d are known
yperparameters and Gamma(c, d) denotes a gamma  distribu-
ion with mean c/d and variance c/d2. It is important to note
hat one or more  of these parameters are alternatively ﬁxed
ith constant values when considering the special cases of the
MW distribution. For example, if considering the exponenti-
ted exponential (EE) distribution, we  have  ˛ ∼ Gamma(c˛, d˛),
 ∼ Gamma(cˇ, dˇ),  = 1 and  = 0. When we  have the presence
f covariates, we  can assume a normal prior distribution N(e,
2) with known mean e and known variance f2 for each param-
ter included in the vector . In all cases we assume prior
ndependence among the parameters included in the model.
osterior summaries of interest are obtained from simulated
amples for the joint posterior distribution using standard
arkov Chain Monte Carlo (MCMC) procedures. Interested
eaders can refer to Chib and Greenberg [49] for a review of
tandard MCMC  methods. We  generated 1,005,000 samples
or each parameter of interest. The 5000 ﬁrst simulated sam-
les were discarded as a burn-in period, which is usually
sed to minimize the effect of the initial values. The pos-
erior summaries of interest were based on 10,000 samples,
aking every 100th sample to have approximately uncorre-
ated values. The Bayes estimates of the parameters were
btained as the median of Gibbs samples drawn from the joint
osterior distribution. We used the median rather than the
ean since some simulated distributions were quite skewed.
or our study, we considered mixture and non-mixture mod-
ls based on the four-parameter GMW  distribution and
ome special cases of this distribution (Weibull, exponential,
ayleigh, extreme value, EW, EE, GR and MW distributions).
onvergence of the MCMC  algorithm was monitored by
sual time series plots for the simulated samples and also
sing some existing Bayesian convergence methods consid-
ring different initial values (see for example Gelman and
ubin [50]).
.1.  Model  selection
omparison between mixture and non-mixture models
ssuming different distributions was assessed using the
eviance information criteria (DIC) proposed by Spiegelhalter
t al. [51], where a lower DIC value indicates better model ﬁt.
he deviance D() is deﬁned by D() = −2 ln L() + k, where  is
he vector of unknown parameters included in the model, L()
s the respective likelihood function and k is a constant that
oes not vary across models. Thus, the DIC value is given by
IC = D(̂) + 2nP = 2D − D(̂), where D(̂) is the deviance eval-
ated at the posterior mean and nP is the effective number
f parameters of the model, given by nP = D− D(̂), consid-
ring D as the posterior deviance measuring the quality of
he data ﬁt for the model. We also obtained the expected
kaike information criterion (EAIC) introduced by Brooks [52],
nd the expected Bayesian (or Schwarz) information criterion o m e d i c i n e 1 1 2 ( 2 0 1 3 ) 343–355 347
(EBIC) proposed by Carlin and Louis [48]. The EAIC and EBIC
values can be calculated by EAIC = D + 2q and EBIC = D +
q ln(n), respectively, where q is the number of parameters
in the model and n is the sample size. OpenBUGS software
was used to calculate the DIC, EAIC and EBIC values and in
the generation of samples from the posterior distribution on
the model parameters. The model code is given in Appendix
A.
5.  Results
For the Bayesian analysis of the mixture and non-mixture
models considering the GMW distribution and not including
covariates, it was assumed p ∼ Beta(1, 1) (a non-informative
uniform prior distribution) and Gamma(1, 1) prior distributions
for ˛, ˇ,  and , that is, c˛ = d˛ = cˇ = dˇ = c = d = c = d = 1. The
convergence of the MCMC algorithm was not obtained using
the software OpenBUGS choosing values less than 1 for these
hyperparameters, even when using a larger burn in period
for the algorithm. In Tables 2 and 3 we  have the posterior
summaries considering the Bayesian approach assuming the
mixture and non-mixture models, respectively. From 2 and 3,
we observe similar results considering both models. We  note
that when we compare the obtained DIC values considering
each one of the assumed probability distributions for the mix-
ture and non-mixture models, we have very similar values.
This suggests that both models (mixture and non-mixture) ﬁt
the data equally well. In addition, to evaluate the robustness of
the method, we performed a small sensitivity analysis study
in which the prior standard deviations for ˛, ˇ,  and  are
speciﬁed to be less than that assuming a Gamma(1, 1) distri-
bution, but the results (not shown) were quite similar. From
both Tables 2 and 3 it is possible to note that the models that
showed the smallest DIC values are those based on the GMW
and EW distributions. However, when these models are com-
pared, we  observe that the smallest EAIC and EBIC values are
those obtained using the MW distribution. In order to obtain
a more  visual representation of the ﬁt of the model for the
data based on the different distributions for the gastric can-
cer data, Fig. 2 shows plots of the Kaplan–Meier estimates for
the survival function against the respective predicted values
obtained from the parametric mixture models (results from
Table 2) for each probability distribution. We omitted the plots
considering the non-mixture models since they are similar to
those obtained by considering the mixture model. Clearly, we
observe from Fig. 2 that the predicted values obtained from the
models based on the GMW and MW distributions are those
closest to the empirical values, suggesting that these mod-
els give a better ﬁt to the data. From Tables 2 and 3 we  also
note that the models based on the Weibull, Exponential, EW
and EE distributions have estimated values for p smaller than
that suggested by Fig. 1. Using the models based on the GMW
and MW distributions we estimated more  realistic values for
the cure fraction p, which shows an additional evidence of a
better ﬁt according to these models, despite the observed DIC
values.
The graphs in Fig. 3 show the survival functions (panels (a)
and (b)) and the respective hazard functions (panels (c) and (d))
obtained from the ﬁt of the mixture model (results in Table 2),
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Table 2 – Posterior summaries, assuming the mixture model and not including covariates.
Model Parameter Posterior median 95% credible interval DIC EAIC EBIC
GMW  ˛ 0.1498 (0.0099; 0.6547) 879.3 897.9 914.4
ˇ 1.3150 (0.5451; 3.5900)
 0.4383 (0.1728; 1.1150)
 0.0565 (0.0248; 0.0985)
p 0.4906 (0.4003; 0.5660)
Standard Weibull ˛  0.0517 (0.0290; 0.0895) 898.6 902.6 917.8
 0.8867 (0.7104; 1.124)
p 0.2683 (0.0181; 0.4737)
Standard exponential  ˛ 0.0462 (0.0259; 0.0699) 898.2 900.5 917.7
p 0.3534 (0.0967; 0.4857)
Standard Rayleigh  ˛ 0.0046 (0.0035; 0.0058) 950.7 952.8 970.0
p 0.4990 (0.4272; 0.5714)
Extreme value  ˛ 0.1324 (0.0843; 0.1985) 941.8 944.9 960.1
 0.1247 (0.1057; 0.1448)
p 0.5006 (0.4282; 0.5735)
Exponentiated Weibull  ˛ 0.0709 (0.0039; 0.4047) 878.0 905.0 918.2
(EW)  ˇ 1.1210 (0.5065; 2.8550)
 0.8094 (0.4087; 1.6420)
p 0.2437 (0.0126; 0.4812)
Exponentiated exponential ˛  0.0357 (0.0160; 0.0698) 898.5 902.4 917.6
(EE)  ˇ 0.8791 (0.6695; 1.1660)
p 0.3031 (0.0310; 0.4728)
Generalized Rayleigh  ˛ 0.0017 (0.0001; 0.0031) 896.0 899.2 914.4
(GR)  ˇ 0.4322 (0.3358; 0.5498)
p 0.4562 (0.2762; 0.5461)
Modiﬁed Weibull  ˛ 0.0808 (0.0455; 0.1346) 891.7 895.7 908.9
(MW)  0.5566 
 0.0643 
p 0.4921 
according to the GMW  distribution and its special cases. The
hazard function h(t) is given by
h(t) = f  (t)
S(t)
= (1 − p)f0(t)
p + (1 − p)S0(t)
, (7)
where f0(t) and S0(t) are given by (3) and (4), respectively. Plots
considering the non-mixture models (not shown) are quite
similar to that obtained for the mixture models (Fig. 3). As
expected, the survival curves associated to the models based
on the GMW  and MW distributions are the closest to the
empirical values from Kaplan–Meier estimates (Fig. 3, panel
(b)). The panel (d) of Fig. 3 shows that the hazard functions
obtained from these distributions are quite close to each
other. These curves suggest that the risk of dying during the
period immediately after the surgery is high. After this peak,
the risk decreases with a slight increase close to the twen-
tieth month and with a further reduction until the end of
follow up.
Table 4 shows the inferences for the models based on
the GMW  distribution and its special cases, not including
the cure fraction p. We can note that the ﬁt of models not
including p gives larger DIC, EAIC and EBIC values than the
ﬁt of models including the cure fraction (see Tables 2 and 3).
As expected, this suggests that the cure fraction models are
more  appropriate for the analysis of this medical lifetime data
set.(0.3307; 0.8550)
(0.0264; 0.0948)
(0.4049; 0.5670)
To obtain inferences considering the type of treatment as
a covariate, we initially considered the regression model
ln
(
pi
1 − pi
)
= 0 + 1xi,
where xi is a “dummy” variable related to the treatment
(1 = adjuvant chemoradiotherapy; 0 = surgery alone), i = 1, . . .,  n.
Assuming the mixture and non-mixture models based on the
GMW distribution, let us consider normal prior distributions
N(0, 100) for the parameters 0 and 1. Thus, we  are assuming
approximately non-informative priors for these parameters.
Note that the parameter 1 is related to the effect of the
treatment on the cure fraction. If the credible interval for 1
includes zero, we can conclude that there is no evidence of
treatment effect. Assuming prior independence among the
parameters, Table 5 shows posterior summaries obtained from
simulated samples using the MCMC method and the graph
representing the survival function obtained from the mix-
ture model is shown in the panel (a) of Fig. 4. The DIC, EAIC
and EBIC values for the two assumed models (Table 5) also
give very close results. The values for p0 and p1 showed in
Table 5 were obtained by the relations p0 = e0 /(1 + e0 ) and
p1 = e0+1 /(1 + e0+1 ) and they refer to the cure fractions consid-
ering the patients treated by surgery alone and adjuvant
chemoradiotherapy, respectively.
The graph in the panel (a) of Fig. 4 suggests that the model
considering the GMW  distribution and a covariate in the cure
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Table 3 – Posterior summaries, assuming the non-mixture model and not including covariates.
Model Parameter Posterior median 95% credible interval DIC EAIC EBIC
GMW  ˛ 0.1176 (0.0052; 0.5719) 877.7 898.0 914.5
ˇ 1.3410 (0.5335; 3.593)
 0.4227 (0.1666; 1.1230)
 0.0626 (0.0276; 0.1100)
p 0.4918 (0.3997; 0.5671)
Standard Weibull ˛  0.0261 (0.0099; 0.0529) 899.6 903.4 918.6
 0.9252 (0.7433; 1.1590)
p 0.2471 (0.0260; 0.4586)
Standard exponential  ˛ 0.0262 (0.0094; 0.0477) 898.5 901.0 918.2
p 0.2996 (0.0664; 0.4606)
Standard Rayleigh  ˛ 0.0038 (0.0027; 0.0049) 947.5 949.5 966.7
p 0.4929 (0.4165; 0.5665)
Extreme value  ˛ 0.0911 (0.0578; 0.1403) 939.3 942.3 957.5
 0.1341 (0.1139; 0.1551)
p 0.4969 (0.4253; 0.5680)
Exponentiated Weibull  ˛ 0.0526 (0.0015; 0.3503) 874.6 905.8 919.0
(EW)  ˇ 1.2860 (0.5272; 3.3440)
 0.7489 (0.3497; 1.6560)
p 0.2022 (0.0139; 0.4628)
Exponentiated exponential ˛  0.0219 (0.0055; 0.0522) 899.3 903.3 918.5
(EE)  ˇ 0.9395 (0.7427; 1.2090)
p 0.2765 (0.0422; 0.4590)
Generalized Rayleigh  ˛ 0.0011 (0.0001; 0.0024) 897.8 901.5 916.7
(GR)  ˇ 0.4680 (0.3716; 0.5836)
p 0.4369 (0.2021; 0.5415)
Modiﬁed Weibull  ˛ 0.0575 (0.0316; 0.0969) 891.8 895.8 909.0
(MW)  0.5524 (0.3213; 0.8555)
 0.0723 (0.0349; 0.1043)
p 0.4931 (0.4081; 0.5675)
Table 4 – Posterior summaries, not including the cure fraction p and not including covariates.
Model Parameter Posterior median 95% credible interval DIC EAIC EBIC
GMW  ˛ 0.1506 (0.0115; 0.6112) 883.9 906.1 919.3
ˇ 1.6030 (0.6819; 4.0630)
 0.5037 (0.2465; 1.0060)
 0.0055 (0.0002; 0.0175)
Standard Weibull  ˛ 0.0430 (0.0252; 0.0700) 898.6 900.7 907.3
 0.8200 (0.6621; 0.9568)
Standard exponential  ˛ 0.0229 (0.0186; 0.0278) 901.3 902.3 905.6
Standard Rayleigh  ˛ 0.00085 (0.0006; 0.0010) 1023.0 1024.0 1027.3
Extreme value  ˛ 0.1038 (0.0705; 0.1462) 1005.0 1007.0 1013.6
 0.0621 (0.0517; 0.0736)
Exponentiated Weibull  ˛ 0.1180 (0.0093; 0.5148) 882.9 903.2 913.1
(EW)  ˇ 1.4710 (0.6771; 3.5800)
 0.6065 (0.3422; 1.1260)
Exponentiated exponential  ˛ 0.0172 (0.0111; 0.0241) 898.6 900.7 907.3
(EE)  ˇ 0.7928 (0.6262; 0.9852)
Generalized Rayleigh  ˛ 0.00016 (0.00008; 0.00029) 899.6 901.7 908.3
(GR)  ˇ 0.3647 (0.2953; 0.4434)
Modiﬁed Weibull  ˛ 0.0463 (0.0267; 0.0755) 900.3 904.1 914.0
(MW)  0.7274 (0.5308; 0.9079)
 0.0056 (0.0002; 0.0198)
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Fig. 2 – Plots of the Kaplan–Meier estimates for the survival function versus the respective predict values obtained from the
parametric mixture models for each probability distribution of interest: (a) GMW,  (b) Weibull, (c) Exponential, (d) Rayleigh, (e)
Extreme value, (f) EW, (g) EE, (f) GR and (g) MW distributions. The diagonal straight lines represent a perfect agreement
between Kaplan–Meier estimates and predicted values.
proportion p was not found to give a good ﬁt for the data, given
that the estimated survival curves are relatively distant from
the Kaplan-Meier curves. Furthermore, we observed that the
curves generated by the Kaplan–Meier for each treatment have
different shapes (Fig. 1, panel (b)). Thus, considering the mix-
ture and non-mixture models based on the GMW distribution,
we  can include the type of treatment as a covariate in the
shape parameter  ˇ by replacing  ˇ by ˇi = exp(0 + 1xi) in the
expressions (5) and (6). Thus, the parameter 1 is related to
the effect of the treatment on the shape of the survival curve.
For a Bayesian analysis we assume normal prior distributions
N(0, 100) for the parameters 0 and 1. Including this covari-
ate both in the cure proportion p and in the shape parameter,
posterior summaries obtained from simulated samples are
showed in Table 6, assuming mixture and non-mixture mod-
els. In this table we  observe again that the DIC, EAIC and EBICvalues for mixture and non-mixture models are quite simi-
lar. Table 6 also shows inferences for the ratio between the
cure proportions p0 and p1. In both models, we  observe that
the 95% credible intervals for p0/p1 include the value 1, indi-
cating that we  do not have evidence of differences between
the population cure fractions considering patients treated by
adjuvant chemoradiotherapy and surgery alone. In addition,
the 95% credible intervals for 1 showed in Table 6 include the
zero value.
Fig. 5 shows the hazard function for death assuming the
mixture model based on the GMW distribution, with a covari-
ate related to type of treatment included both in the cure
proportion p and in the shape parameter  ˇ (results in Table 6).
This ﬁgure evidences the non-proportionality of the hazard
functions, making attractive the use of parametric models for
the analysis of these data since these models do not consider
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Fig. 3 – Plots of the survival functions estimated from the mixture model based on the GMW  distribution and its special
cases (panels (a) and (b)). Panels (c) and (d) exhibit the respective hazard functions. Curves considering the GMW
distribution are showed in all plots for the purpose of comparisons.
Table 5 – Posterior summary, assuming mixture and non-mixture models based in the GMW  distribution and with a
covariate included in the cure proportion p.
Model Parameter Posterior median 95% credible interval DIC EAIC EBIC
Mixture model  ˛ 0.1512 (0.0095; 0.6359) 879.3 899.4 919.2
ˇ 1.3180 (0.5321; 3.5980)
 0.4396 (0.1750; 1.1220)
 0.0562 (0.0223; 0.0959)
0 −0.2185 (−0.7350; 0.1782)
1 0.4351 (−0.1880; 1.0830)
p0 0.4456 (0.3241; 0.5444)
p1 0.5534 (0.4153; 0.6678)
Non-mixture model  ˛ 0.1169 (0.0069; 0.5433) 878.2 896.6 916.4
ˇ 1.3430 (0.5791; 3.4980)
 0.4253 (0.1692; 1.0040)
 0.0630 (0.0283; 0.1144)
0 −0.2950 (−0.7710; 0.0986)
1 0.6265 (0.0350; 1.2210)
p0 0.4268 (0.3163; 0.5246)
p1 0.5821 (0.4536; 0.6904)
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Fig. 4 – (a) Survival functions estimated by the Kaplan–Meier method (black lines) and assuming a mixture model based in
the GMW  distribution with a covariate included in the cure proportion p (red lines). (b) Survival functions from the mixture
model with a covariate included both in the cure proportion p and in the shape parameter  ˇ (red lines). (For interpretation of
erredthe references to color in this ﬁgure legend, the reader is ref
the assumption of proportional hazards used in the usual
semi-parametric Cox model [2]. In addition, the shape of the
curves are very different, suggesting that parametric models
based on generalized probability distributions can be very use-
ful in the analysis of data similar to those shown in Table 1,
since these models can accommodate many  forms of the haz-
ard rate function. Note that the 95% credible intervals for 1
showed in Table 6 do not include the zero value, suggest-
ing a signiﬁcant difference between the shapes of the hazard
Table 6 – Posterior summary, assuming mixture and non-mixtu
covariate included in the cure proportion p and in the shape pa
Model Parameter Posterior median 
Mixture model  ˛ 0.3843 
0 0.6252 
1 1.3070 
 0.3784 
 0.0385 
0 −0.1420 
1 0.2831 
p0 0.4646 
p1 0.5345 
p0/p1 0.8706 
Non-mixture model  ˛ 0.2967 
0 0.5944 
1 1.1490 
 0.3842 
 0.0427 
0 −0.1253 
1 0.2571 
p0 0.4687 
p1 0.5321 
p0/p1 0.8815  to the web version of the article.)
functions. The graphs in Fig. 5 suggest that the hazard of
death is higher in the time immediately after the surgery
considering the patients that received the surgery alone, and
the hazard of death is higher around 20 months after the
surgery intervention, considering the patients that received
the chemoradiotherapy. In many  studies published in med-
ical journals, graphs similar to that showed in Fig. 5 may
be employed in addition to the usual Kaplan-Meier curves
and the correspondent survival functions obtained from
re models based in the GMW  distribution and with a
rameter ˇ.
95% credible interval DIC EAIC EBIC
(0.0190; 1.9280) 814.9 876.8 899.9
(−0.6666; 2.6400)
(0.8114; 1.7820)
(0.1101; 1.1870)
(0.0140; 0.0694)
(−0.5489; 0.2407)
(−0.4207; 0.8930)
(0.3661; 0.5599)
(0.3754; 0.6548)
(0.6443; 1.2510)
(0.0120; 1.4900) 819.8 877.0 900.1
(−0.6499; 2.3390)
(0.7026; 1.6070)
(0.1177; 1.3080)
(0.0155; 0.0766)
(−0.5396; 0.2367)
(−0.4109; 0.8503)
(0.3683; 0.5589)
(0.3809; 0.6505)
(0.6585; 1.2400)
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Fig. 5 – Hazard functions obtained from the mixture model
with a covariate (type of treatment) included both in the
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arametric models, since they are able to describe quite clearly
he death rate at time t.
Graphs similar to that in Figs. 4 and 5 but considering the
on-mixture models are not shown in this article because they
re quite similar to these ones.
.  Discussion
ased on the GMW  distribution, we propose in this article
 cure fraction regression model very suitable for modeling
ensored and uncensored lifetime data. This model extends
everal distributions widely used in the lifetime data analysis
llowing ﬂexibility in modeling monotone and non-monotone
hape hazard rates and it serves as a good alternative for the
nalysis of real data sets. Aiming to show the ﬂexibility, prac-
ical relevance and applicability of this regression model, we
rovided an application to gastric cancer lifetime data. Other
actors different of the treatments may also contribute to the
ariability of the results such as length of illness, the time
rom prognosis to treatment, age at diagnosis and stage of
umor. However, our aim in this study was to describe the util-
ty of the GMW  distribution considering a real data set, and
ore complete models can be developed to study the simul-
aneous effect of a large number of variables on the time until
he event of interest. Bradburn et al. [1] argue that the Cox
roportional hazards model [2] is the most commonly used
pproach for analyzing survival time data in applied medical
esearch. However, this model assumes that for the compar-
son of two groups the respective hazards are proportional
nd not overlapping at all points in time. This assumption
ay not be valid in many  practical situations and the hazardatios obtained in this case are unrealistic. Clearly, the graph
f Fig. 5 evidences non-proportionality in the hazard func-
ions considering patients treated with chemoradiotherapy o m e d i c i n e 1 1 2 ( 2 0 1 3 ) 343–355 353
and with surgery alone. In addition, the standard Cox model
usually does not consider the presence of long time survivors
that are common in many  clinical studies. There are in the
literature, however, several extensions of the Cox model that
account for a surviving fraction [53–55], but these approaches
are not suitable for the assessment of non-proportional hazard
functions. Thus, parametric models including a cure fraction
are suitable tools for the analysis of time-to-event data since
these models do not assume proportional hazards and they
are able to estimate measures which are easily interpreted by
physicians and other health professionals, as the proportions
of long-term survivals and the mean survival time. Therefore,
it is of fundamental importance that statisticians working in
medical research have a good knowledge of different existing
lifetime parametric models, including Bayesian procedures.
It was shown that usual distributions such as Weibull do
not ﬁt well to the data presented in Table 1. The literature
presents many  models based on generalized distributions,
such as the generalized F distribution [56] and the extended
family of the generalized Gamma  distribution [57]. These mod-
els can be satisfactorily used in the analysis of the data set
introduced here, but the purpose of the present study is to
describe the use of a distribution recently introduced in the
literature [7]. New and more  ﬂexible probability distributions
useful for lifetime analysis have been introduced in recent
years by many  researchers (we can cite as examples the works
of Cordeiro et al. [58], Pascoa et al. [59], Cancho et al. [60]
and Roman et al. [61], amongst others), and the use of sta-
tistical models based in these distributions can provide large
beneﬁts for the medical research, as observed in the medi-
cal application introduced in this paper. In addition, Bayesian
inference methods show great potential for efﬁcient comput-
ing likelihood-based inference in a large number of contexts
and the application of models under a Bayesian framework is
often greatly facilitated by the availability of softwares such as
OpenBUGS, that only requires the speciﬁcation of the distri-
bution to the data and prior distributions for the parameters.
Due to the development of MCMC algorithms the application
of Bayesian methods became advantageous to ﬁt models with
many  parameters, which may be difﬁcult to be ﬁtted by fre-
quentist methods. Another advantage of the Bayesian model
is that they also allow the incorporation of expert prior opin-
ion for the parameters. In this way, the professional knowledge
of an oncologist on expected proportion of patients who  are
immune to the event of interest can be incorporated into a
prior distribution for the parameter p, resulting in more  pre-
cise inferences.
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Appendix  A.  OpenBUGS  codesThe OpenBUGS code used for the analysis of the gastric cancer
data is given below, considering the mixture model.
 s i n b i o m e d i c i n e 1 1 2 ( 2 0 1 3 ) 343–355
lambda*t[i])
mbda*t[i]))
(lambda*t[i])),1-beta)
lambda*t[i])),beta)
-p)*S0[i],1-d[i])
r354  c o m p u t e r m e t h o d s a n d p r o g r a m
model
{
for (i in 1:N) {
f0A[i] < -alpha*beta*pow(t[i],gamma-1)*(gamma+
*exp(lambda*t[i]-alpha*pow(t[i],gamma)*exp(la
f0B[i] < -pow(1-exp(-alpha*pow(t[i],gamma)*exp
f0[i] < - f0A[i]/f0B[i]
S0[i] < -1-pow(1-exp(-alpha*pow(t[i],gamma)*exp(
L[i] < -pow(1-p,d[i])*pow(f0[i],d[i])*pow(p+(1
logL[i] < - log(L[i])
zeros[i] < - 0
zeros[i] ∼ dloglik(logL[i])
}
# Prior distributions
p ∼ dbeta(1,1)
alpha ∼ dgamma(1,1)
beta ∼ dgamma(1,1)
gamma ∼ dgamma(1,1)
lambda ∼ dgamma(1,1)
}
In this code, N is the sample size, f0[i] is the baseline
probability density function given in expression (3), S0[i] is
the respective survival function given in expression (4), L[i]
is the likelihood function, t[i] is the time-to-event variable
and d[i] is the censoring indicator variable (denoted by ıi).
Considering that the GMW  distribution is not available directly
as a choice in OpenBUGS we used the dloglik() distribution,
which requires us to specify the logarithm of the likelihood
function. Assuming the non-mixture model, we replace in the
code the line for L[i] by
F0[i]< - 1-S0[i]
h[i] < - -(log(p))*f0[i]
L[i] < - pow(h[i],d[i])*exp(F0[i]*log(p))
In obtaining the posterior samples of the model parame-
ters, we  did not encounter a problem of convergence in any of
the models. However, it is highly recommended that reason-
able initial values are speciﬁed for the generation of samples.
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